ClinicalTrialsFinder

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation Clinical Trials in Nanjing

1 recruitingNanjing, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University30 enrolled1 locationNCT07438106